key: cord-0836297-oyplh9cn
authors: Chuang, David T.; Aydemir, Seyhmus; Magda, Paul; Thomas, Crystal; Zarnegar, Reza
title: Neurological manifestations as primary presentation of COVID‐19 in hospitalized patients
date: 2021-02-09
journal: Acta Neurol Scand
DOI: 10.1111/ane.13399
sha: 267c580f46c058a52c806470cb0e7babf400e012
doc_id: 836297
cord_uid: oyplh9cn

OBJECTIVE: To characterize patients with coronavirus disease 2019 (COVID‐19) who presented primarily with neurologic symptoms without typical COVID‐19 symptoms of fever, cough, and dyspnea. METHODS: We retrospectively identified COVID‐19‐positive patients 18 years and older that had neurology symptoms on presentation requiring neurology consultation between March 14, 2020 and May 18, 2020. The patients were then classified into those with typical COVID‐19 symptoms and those without. Demographic, clinical symptoms, laboratory result, and clinical outcomes were collected. RESULTS: Out of 282 patients who had neurology consult during this period, we identified 56 (mean age 69.2 years, 57% women) who tested COVID‐19‐positive and had neurologic symptoms on initial presentation. Of these, 23 patients (mean age 65.2 years, 52% women) had no typical COVID‐19 symptoms while 33 did (mean age 72.2 years, 60% woman). In both groups, impaired consciousness was the most common initial neurologic symptom, followed by stroke, unsteady gait, headache, seizure, syncopal event, acute vision changes, and intracranial hemorrhage. Out of the 23 patients without typical COVID‐19 symptoms on presentation, 10 went on to develop typical symptoms with 8 needing supplemental oxygen and one requiring mechanical ventilation. CONCLUSION: Patients who have COVID‐19 can present with serious neurologic symptoms such as impaired consciousness and stroke even without typical COVID‐19 symptoms. Those without typical COVID‐19 symptoms can later develop typical symptoms severe enough to need respiratory support.

and hemorrhagic stroke, Guillain-Barre Syndrome, smell/taste dysfunction, and seizures. [5] [6] [7] [8] [9] [10] [11] [12] [13] Of these, the commonly found neurologic symptoms included impaired consciousness, dizziness, and headaches. 5, 6, [8] [9] [10] [11] [12] [13] [14] We report on neurologic symptoms found in COVID-19 patients at an academic community hospital in Queens, New York. New York City's borough of Queens was particularly hit hard being one of the top county by death toll in the whole USA. 15 We focused on neurologic symptoms on presentation in COVID-19-positive patients, specifically those without any typical symptoms, as these patients would raise less concern for COVID-19 and be easily missed.

This is a single-center retrospective study with data from New York Presbyterian Queens, a tertiary care community hospital serving a racial and ethnic diverse population of over 2 million in Queens, New York. 16 The time period of this study was between March 14, 2020 and May 18, 2020, at the peak of the COVID-19 epidemic in Queens. 17 All charts for admitted patients older than 18 years old that had neurology consultations during the study period were reviewed for those that tested positive for SARS-CoV-2 based on highthroughput sequencing or real-time reverse-transcription polymerase chain reaction (RT-PCR) analysis of upper respiratory tract specimens.

From this group, we identified those that had neurologic symptoms on presentation. Of the patients who had symptoms on initial presentation, we divided them into those who had typical COVID-19 viral symptoms and those that did not. We used the CDC's definition of typical COVID-19 symptoms, which are fever, cough, and dyspnea. 3, 4 The presence of fever as a symptom was included if subjectively reported by the patient or if the temperature was elevated above 38.0° Celsius. All patients included in the study were followed until discharge or death. For patients who never had typical COVID-19 symptoms, we checked to see if they returned to the emergency room within a month after discharge for typical COVID-19 symptoms.

We classified the neurologic symptoms as impaired consciousness, stroke (acute and subacute), seizure, headache, intracranial hemorrhage, unsteady gait, syncopal event (including pre-syncopal symptom such as dizziness), and acute vision changes. The symptoms were recorded based on clinician notes from the electronic medical records. The diagnosis of stroke and intracranial hemorrhage was based on neuroimaging.

Institutional Review Board and need for informed consent was waived as study was minimal risk and not practical to conduct without waiver.

For each SARS-CoV-2-positive patient with neurologic symptoms on initial presentation, data were collected which includes demographics, radiology results (including MRI, CT and chest X-ray), laboratory values, clinical symptoms, length of stay, and overall inhospital mortality.

Comparison was made between the group that had typical COVID-19 symptoms versus the group that did not. Mann-Whitney U test was Table 1 . Their mean age was 69.2 years old (standard deviation of 17.1), and 57 percent were female. Racial breakdown was 23% Asian, 21% White, 20% Black, and 36% others (which included Hispanic).

Hypertension was the most common comorbidity at 82.1%, followed by hyperlipidemia (60.7%), diabetes (50%), history of stroke (29%), coronary artery disease (27%), chronic kidney disease (21%), obesity with BMI > 30 kg/m 2 (21%), and COPD/Asthma (7%).

In our 56 COVID-19 patients who had neurologic symptoms on presentation, impaired consciousness was the most common (45%), followed by stroke ( with subacute stroke), unsteady gait (20%), headache (13%), seizure (11%), syncopal event (9%), acute vision changes (5%), and intracranial hemorrhage (4%). The overall in-hospital mortality rate was 21%, and the median length of stay was 8 ± 3.2-14 days.

Of the patients with neurologic and typical COVID-19 symptoms on presentation (n = 33), the most common neurologic symptom was impaired consciousness (45%), followed by stroke (10/ The laboratory results of our patient group are summarized in Table 1 . The group without typical COVID-19 symptom was noted to have significantly lower median serum creatinine (0.86 vs. 1.04 mg/ dl, p = .04). The markers of inflammation were noted to be higher in the group with typical COVID-19 symptoms, but no statistical significance was reached. When we looked at the total number of stroke patients who had D-dimers checked (n = 8, mean = 14,686 ng/ ml) versus non-stroke patients who had D-dimer checked (n = 23, mean = 2,000 ng/ml), we found that stroke patients had significantly higher D-dimer (p = .015). The subgroup of patients who had stroke without typical COVID-19 symptoms and had D-dimer tested were too small to draw a conclusion regarding whether D-dimer is elevated in this subset of patients.

There was no statistical difference in demographics and comorbidities between the group with typical COVID-19 symptoms and the group without (Table 1 ). There was also no statistical difference in neurologic symptomatology, overall in-hospital mortality, and length of stay between the two groups.

The neurological manifestations associated with COVID-19 have There was no significant difference in rate of presentation with neurologic symptoms between those with typical COVID-19 symptoms and those without, including for more serious neurologic manifestations such as impaired consciousness and stroke. We also did not find significant difference in overall mortality and length of stay between these two groups. This is not surprising given our small sample size. has been attributed to endovascular injury and a prothrombotic state. 18, 19 It has also been found that COVID-19 is more likely to cause stroke than other viral illness such as influenza. 18 We found those who had stroke had higher D-dimer levels consistent with prior reports. 14, 18 The existing literature is mixed on stroke occurrence at COVID-19 onset. One study found no stroke at COVID-19

presentation, 13 whereas others found varied rate from less than what we found to rates closer to ours. 5, 11, 21 Overall, it was rare for COVID- 19 One of the challenges of this study is determining if the neurological symptoms were related to SARS-CoV-2 or a coincidental finding given that COVID-19 infection can be asymptomatic. 20 Many of the neurologic symptoms seen with COVID-19, such as headache and unsteadiness, are non-specific and seen in viral illness and other disease states. Despite that, many earlier studies have included nonspecific neurologic symptoms. [8] [9] [10] [11] [12] [13] The benefit of our methodology is even if the neurologic symptom seems non-specific, they precipitated neurology consults.

The strength of our paper is that all included patients were evaluated by a neurologist which was not done with some of the earlier papers. 5, 8, 10, 13 All patients in the study were confirmed to have 

intubation and sedation, and thus, many of their neurologic conditions would have been missed.

Much attention is given to the presence of fever, cough, and dyspnea as symptoms of COVID-19, with neurologic symptoms also commonly seen on presentation. Our study shows COVID-19 patients can have neurologic manifestation severe enough to warrant neurology consultation in the absence of typical COVID-19 symptoms.

This can include serious neurologic manifestations such as stroke and impaired awareness. Many of these patients can later deteriorate to need respiratory support. Thus, it is important to screen for SARS-CoV-2 in patients who present with neurologic symptoms even if without common typical symptoms.

None.

The authors declare they have no conflict of interest and no disclosures.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

David T. Chuang https://orcid.org/0000-0002-7568-369X

A novel coronavirus from patients with pneumonia in China

WHO. Naming the coronavirus disease (COVID-19) and the virus that causes it

Symptom profiles of a convenience sample of patients with COVID-19 -United States

Presymptomatic SARS-CoV-2 infections and transmission in a nursing facility

Neurologic manifestation of hospitalized patients with coronavirus disease 2019 in Wuhan China

Neurologic features in severe SARS-COV-2 infection

Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms

New onset neurologic events in people with COVID-19 in 3 regions in China

Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia

Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry

A prospective study of neurologic disorders in hospitalized COVID-19 patients in New York City

Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII hospital

Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients

SARS-CoV-2 and stroke in a New York healthcare system

Johns Hopkins coronavirus resource center

Where America's diversity is increasing the fastest. Axios

COVID-19 outbreak

Risk of ischemic stroke with coronavirus disease 2019 (COVID-19) vs patients with influenza

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19